Non small cell lung cancer
Conditions
Interventions
treatment group:Docetaxel: 75mg/m2, intravenous drip, day1, repeated every 21 days. Endostatin: 15mg, intravenous drip, day1-14, repeated every 21 days.
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Pathologically proved non small cell lung cancer; 2. Over age of 18; 3. At least one EGFR-TKI was prior used; 4. One and only one chemotherapy regimen was administered ahead of EGFR-TKI; 5. Tumor progression was detected after EGFR-TKI treatment; 6. No chemotherapy or radiation was administered after EGFR-TKI treatment; 7. Evaluable tumor mass was present; 8. Performance status as ECOG 0-2; 9. No contraindication to chemotherapy; 10. Expectation of life was over 12 weeks; 11. Voluntary participation and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Not controlled brain metastasis; 2. Only unevaluable tumor was present; 3. Target tumor needs local treatment; 4. Hypersensitiveness to bacillus coli praeparatum; 5. Combined with any unstable systemic diseases; 6. Disturbances of blood coagulation, active bleeding or hemorrhagic tendency; 7. Having contraindications to docetaxel or endostatin according to the directions; 8. Pregnancy or lactation; 9. Having serious heart disease; 10. Any conditions that the investigator regards to be not suitable for current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response Rate;Progression Free Survival;Grade 4 toxicities; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactDr. Jiang Zhu
Outcome results
None listed